H169

H169 is a high-affinity, sub-nanomolar (R)-azetidine-2-carboxamide-based small molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) activity. Developed by researchers at Cedars-Sinai Medical Center and the University of Hawaii at Manoa, H169 selectively binds to STAT3 (with a KD of 1 pM) and inhibits its DNA-binding activity and phosphorylation. In preclinical studies, H169 has demonstrated potent in vitro activity against triple-negative breast cancer (TNBC) cells, suppressing anchorage-dependent and independent growth, inducing apoptosis, and downregulating downstream STAT3 target genes such as c-Myc, VEGF, and survivin. It also shows synergistic effects when combined with docetaxel.